for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sierra Oncology Inc

SRRA.OQ

Latest Trade

0.42USD

Change

-0.05(-9.68%)

Volume

42,075

Today's Range

0.42

 - 

0.47

52 Week Range

0.40

 - 

2.01

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.47
Open
0.47
Volume
42,075
3M AVG Volume
8.77
Today's High
0.47
Today's Low
0.42
52 Week High
2.01
52 Week Low
0.40
Shares Out (MIL)
74.69
Market Cap (MIL)
33.87
Forward P/E
-0.55
Dividend (Yield %)
--

Next Event

Q3 2019 Sierra Oncology Inc Earnings Release

Latest Developments

More

Sierra Oncology Reports Second Quarter 2019 Results

Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets

Sierra Announces Momelotinib Granted FDA Fast Track Designation

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sierra Oncology Inc

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.

Industry

Biotechnology & Drugs

Contact Info

2150 ? 885 West Georgia Street

+1.604.5586536

http://sierraoncology.staging.wpengine.com/

Executive Leadership

Donald R. Parfet

Independent Chairman of the Board

Nicholas R. Glover

President, Chief Executive Officer, Director

Sukhi Jagpal

Chief Financial Officer

Barbara Klencke

Chief Development Officer

Mark Kowalski

Chief Medical Officer

Key Stats

1.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.580

2017

-0.840

2018

-0.750

2019(E)

-0.815
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.48
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.05
LT Debt To Equity (MRQ)
6.11
Return on Investment (TTM)
-58.97
Return on Equity (TTM)
-54.31

Latest News

BRIEF-Sierra Oncology Reports Qtrly Loss Per Share $0.19

* SIERRA ONCOLOGY INC - SRA737 MONOTHERAPY PHASE 1/2 TRIAL EXPANDED TO ENROLL CCNE1-DRIVEN OVARIAN CANCER COHORT

BRIEF-Sierra Oncology Announces Pricing Of Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sierra Oncology Announces Proposed Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sierra Oncology Significantly Expands Clinical Development Program

* SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM

BRIEF-Sierra Oncology Reports Qtrly Loss Of $0.20 Per Share

* SIERRA ONCOLOGY INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.20

BRIEF-Sierra Oncology reports net loss $0.19 per share

* Qtrly net loss per share, basic and diluted $0.19 Source text for Eikon: Further company coverage:

BRIEF-Sierra Oncology appoints Dr. Andrew Allen to board

* Sierra Oncology appoints Dr. Andrew Allen to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Sierra Oncology establishes DNA damage response advisory committee

* sierra Oncology - establishes DNA damage response advisory committee Source text for Eikon: Further company coverage:

BRIEF-Sierra Oncology reports qtrly loss per share $‍0.20​

* on track to provide preliminary update from CHK1 inhibitor SRA737 clinical trials in early 2018

BRIEF-Sierra Oncology granted U.S., EU patents for CHK1 inhibitor SRA737

* Sierra Oncology granted U.S. and EU patents for CHK1 inhibitor SRA737 Source text for Eikon: Further company coverage:

BRIEF-Sierra Oncology granted U.S, EU patents for Chk1 inhibitor SRA737

* Sierra Oncology granted US and EU patents for Chk1 inhibitor SRA737

BRIEF-Sierra Oncology Receives clearance to enhance ongoing clinical trials for SRA737

* Says received clearance from regulators in UK to amend two ongoing phase 1 trials for its CHK1 inhibitor, SRA737

BRIEF-Sierra Oncology Inc Q1 net loss per share $0.26

* Q1 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Sierra Oncology reports preclinical synthetic lethality data for chk1 inhibitor sra737 at aacr

* Sierra Oncology Inc - Sierra Oncology collaborator ICR reports preclinical synthetic lethality data for chk1 inhibitor sra737 at aacr

BRIEF-Sierra Oncology Inc - Q4 net loss per share attributable to common stockholders $0.30

* Sierra Oncology Inc -" existing cash and cash equivalents will be sufficient to fund our current operating plans through approximately mid-2019"

BRIEF-Frazier Healthcare VI L.P. reports 16.28 percent stake in Sierra Oncology as on Feb 14 - SEC filing

* Frazier Healthcare VI L.P. reports 16.28 percent stake in Sierra Oncology as on February 14, 2017 - sec filing Source text: (http://bit.ly/2l8KPD5) Further company coverage:

BRIEF-Sierra Oncology announces proposed public offering of common stock

* Sierra Oncology announces proposed public offering of common stock Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up